One significant difference between our project and other deep-learning drug discovery projects is its application on FDA-approved drugs. The repurposing of FDA-approved drugs has many practical benefits, especially for p38 inhibitors. Many of the most common and potent p38 inhibitors do well in in vitro experiments but fall short during in vivo or human trials due to unexpected side effects or issues with toxicity (Hammaker & Firestein, 2010). When repurposing approved drugs, however, the safety of the compound has been studied extensively by the FDA and often other organizations like the European Medicines Agency (EMA). This not only ensures that a drug is safe and its side effects are well documented, but it also significantly cheapens and shortens the researcher to patient pipeline, which normally takes an average of 10-15 years, because doctors can provide off-label prescriptions before official approval. Thus, if clinical trials bode well, these inhibitors could very soon be available to patients suffering from potentially life-threatening p38-mediated diseases.